Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Prokarium Acquires Emergent’s Oral Vaccine Technology | Contract Pharma

What are you searching for?

Sign in
Breaking News

Prokarium Acquires Emergent’s Oral Vaccine Technology

Will develop an advanced oral delivery platform

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Prokarium Ltd. has acquired Emergent BioSolutions’ live Salmonella-based typhoid vaccine, Typhella, and its genetic technology spi-VEC. Prokarium will combine Typhella and spi-VEC with its genetic and formulation technologies to form Vaxonella, an oral vaccine delivery platform.
 
Emergent has conducted several Phase I and II trials that have shown Typhella to be safe and immunogenic as a typhoid vaccine. The combination with Prokarium’s plasmid stabilization technology, ORT-VAC, will enable the delivery of recombinant protein vaccines without needles or adjuvants. Prokarium plans to offer this Vaxonella platform to the biopharma community on a licensing basis.
 
Dr. Rocky Cranenburgh, Prokarium’s chief scientific officer, said, “I am delighted with the acquisition of this technology from Emergent; the combination of their Salmonella vector with Prokarium’s technologies allows us to develop an advanced oral delivery platform which gives Prokarium the potential to revolutionize vaccinations.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics